Printer Friendly

IMMUNOMEDICS COMPLETES OFFERING OF 2 MILLION SHARES OF COMMON STOCK COMPANY EXPANDS FACILITIES

           IMMUNOMEDICS COMPLETES OFFERING OF 2 MILLION SHARES
               OF COMMON STOCK COMPANY EXPANDS FACILITIES
    WARREN, N.J., Jan. 30 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU) announced the public offering of 2 million new shares of common stock priced at $14 a share.  The shares are being offered through Allen and Company Incorporated, Kemper Securities Group, Inc. and SBCI Swiss Bank Corporation Investment Banking, Inc.
    "This offering is a strong indication of investors' in Immunomedics' future and in the company's ability to continue to meet its objectives," noted Amy Factor, vice president, finance and administration.  "The proceeds of the offering will bring our cash position to over $50 million.  This funding will be used for the construction of a commercial scale manufacturing facility to meet future worldwide product demand and for the company's clinical trial and research programs.  We have seven products currently in clinical trials in the United States, clinical activity is accelerating in Europe and various potential cancer therapeutics are currently in preclinical testing," further noted Factor.
    The company recently entered into a lease for a new facility, located in Morris Plains, N.J., which will be the site of the company's commercial scale manufacturing facility, research and development activities and corporate offices.  Renovation of the company's Newark facility is nearing completion, and the facility is designed to meet the initial demand of the company's colorectal cancer product, ImmuRAID-CEA, which is now under review at the U.S. Food and Drug Administration.
    Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases.  Integral to these products are highly specific nonoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases.
    -0-        1/30/92
    /CONTACT:  Amy Factor of Immunomedics, 908-647-5400/
    (IMMU) CO:  Immunomedics Inc. ST:  New Jersey IN:  MTC SU:  OFR SM-TM -- NY030 -- 5144 01/30/92 10:19 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 30, 1992
Words:326
Previous Article:HARMAN INTERNATIONAL INDUSTRIES, INCORPORATED, ANNOUNCES SECOND QUARTER AND FIRST HALF FISCAL 1992 RESULTS
Next Article:YELLOW FREIGHT RELEASES FOURTH QUARTER FINANCIAL RESULTS
Topics:


Related Articles
IMMUNOMEDICS FILES REGISTRATION STATEMENT WITH SEC
IMMUNOMEDICS REPORTS SECOND QUARTER RESULTS OF OPERATIONS
IMMUNOMEDICS AMENDS INVESTOR WARRANT AGREEMENT
IMMUNOMEDICS REPORTS FISCAL 1992 FINANCIAL RESULTS
IMMUNOMEDICS ANNOUNCES THIRD QUARTER 1993 FINANCIAL RESULTS IN LINE WITH COMPANY EXPECTATIONS
IMMUNOMEDICS COMPLETES $10 MILLION FINANCING
Immunomedics Structures $30 Million Flexible Equity Line Financing

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters